Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GIM-122 in Advanced Solid Malignancies
NCT06028074Phase 2Recruiting
- Sponsor
- Georgiamune
- Start
- Dec 2023
- Primary completion
- Sep 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of GIM-122 in solid tumor, sponsored by Georgiamune. Primary endpoints: Dose limiting toxicities at 18 months, Maximum tolerated dose at 18 months and 4 more. Started Dec 2023; status: recruiting.
02
Drugs
GIM-122
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06028074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06028074.